Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients Previously Undiagnosed Peripheral T-cell Lymphoma Who Achieved an Objective Response After Initial Treatment With CHOP-based Chemotherapy

The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in patients with partial response following CHOP-based chemotherapy. Patients will either receive pralatrexate or be under observation. All patients will receive vitamins B12 and folic acid and attend regular clinic visits to evaluate their disease and health.

Study Overview

• Status: Terminated
• Conditions: Peripheral T-cell Lymphoma
• Intervention / Treatment: Drug: Pralatrexate Injection

Detailed Description

This was an international, multi-center, randomized, Phase 3, open-label study of sequential pralatrexate versus observation in patients with previously undiagnosed PTCL who have achieved an objective response following initial treatment with CHOP-based chemotherapy.

Upon documentation of completion of an objective response following at least 6 cycles of a designated CHOP-based chemotherapy confirmation of histopathology by independent review, and confirmation that all eligibility criteria were met, patients were randomized in a 2:1 ratio to either pralatrexate or observation, according to a permuted block design with stratification factor of Tumor Response per Investigator at completion of CHOP-based therapy (Complete Response [CR] vs Partial Response [PR]).

All patients who receive at least 1 dose of pralatrexate were followed for safety through 35 (± 5) days after their last dose of pralatrexate or until all treatment-related AEs have resolved or returned to baseline/Grade 1, whichever is longer, or until it was determined that the outcome does not change with further follow-up.

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • Royal Adelaide Hospital
    • Bedford Park, South Australia, Australia, 5042
      • Flinders Medical Center
  • Tasmania
    • Hobart, Tasmania, Australia, 7001
      • Royal Hobart Hospital
  • Victoria
    • Clayton, Victoria, Australia, 3168
      • Monash Medical Centre
    • Fitzroy, Victoria, Australia, 3109
      • Saint Vincent's Hospital Melbourne
    • Frankston, Victoria, Australia, 3199
      • Frankston Hospital
    • Malvern, Victoria, Australia, 3144
      • Cabrini Health
  • Western Australia
    • Perth, Western Australia, Australia, 6000
      • Royal Perth Hospital
• Belgium
  • Brugge, Belgium, 8000
    • AZ Sint-Jan
  • Gent, Belgium, 9000
    • Universitair Ziekenhuis Gent
• Canada
  • Ontario
    • Toronto, Ontario, Canada, M4N 3M5
      • Sunnybrook Health Science Centre
  • Quebec
    • Montreal, Quebec, Canada, H4J 1C5
      • Hopital du Sacre-Coeur de Montreal
• France
  • Brest, France, 29609
    • Hôpital Morvan
  • Pessac, France, 33604
    • Chu Haut-Leveque
• Ireland
  • Dublin 8, Ireland
    • St James Hospital
• Israel
  • Jerusalem, Israel, 91031
    • Shaare Zedek Medical Center
  • Jerusalem, Israel, 91120
    • Hadassah Ein-Kerem Medical Centre
  • Petach Tikva, Israel, 49100
    • Rabin Medical Center
  • Tel Hashomer, Israel, 52621
    • Chaim Sheba Medical Center
• Italy
  • Bologna, Italy, 40138
    • Az. Ospedaliera Universitaria S. Orsola Malpighi
  • Brescia, Italy, 25123
    • Spedali Civili di Brescia
  • Ravenna, Italy, 48121
    • Ospedale S. Maria Delle Croci
  • Roma, Italy, 00168
    • Universita Cattolica del Sacro Cuore
  • Siena, Italy, 53100
    • Az. Ospedaliera Università Senese
  • Forli
    • Meldola, Forli, Italy, 47014
      • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
• New Zealand
  • Auckland, New Zealand, 1010
    • Auckland City Hospital / Auckland University
  • Christchurch, New Zealand, 8011
    • Christchurch Hospital
  • Milford, New Zealand
    • North Shore Hospital
  • Auckland
    • Otahuhu, Auckland, New Zealand, 1640
      • Middlemore Hospital
• Poland
  • Gdansk, Poland, 80-952
    • Dept of Hematology and Transplantology
  • Kraków, Poland, 30-510
    • Małopolskie Centrum Medyczne
  • Mazowieckie
    • Warszawa, Mazowieckie, Poland, 02-781
      • Klinika Nowotworów Ukladu Chlonnego Centrum Onkologii Instytut Marii Sklodowskiej-Curie
• Puerto Rico
  • San Juan, Puerto Rico, 00918
    • Auxilio Mutuo Cancer Center
• Spain
  • A Coruña, Spain, 15006
    • Complejo Hospitalario Universitario A Coruña- Hospital A Coruña
  • Barcelona, Spain, 08036
    • Hospital Clinic i Provincial de Barcelona
  • Barcelona, Spain, 08035
    • Hospital General Vall D'Hebron
  • Madrid, Spain, 28034
    • Hospital Universitario Ramon y Cajal
  • Madrid, Spain, 28050
    • Hospital de Madrid Norte-Sanchinarro
  • Madrid, Spain, 28222
    • Hospital Universitario Puerta de Hierro Majadahonda
  • Navarra
    • Pamplona, Navarra, Spain, 31008
      • Clinica Universidad de Navarra
    • Pamplona, Navarra, Spain, 31008
      • Complejo Hospitalario de Navarra, Servicio de Hematologia
• United Kingdom
  • Belfast, United Kingdom, BT9 7AB
    • Belfast City Hospital
  • Cardiff, United Kingdom, CF14 2TL
    • Velindre Hospital
  • Liverpool, United Kingdom, L7 8XP
    • Royal Liverpool University Hospital
  • Middlesex, United Kingdom, HA6 2RN
    • Mount Vernon Cancer Centre
  • Warwick, United Kingdom, CA34 5BW
    • UHCW (University Hospital Coventry and Warwickshire)
  • Cornwall
    • Truro, Cornwall, United Kingdom, TR1 3LJ
      • Royal Cornwall Hospital
  • Dorset
    • Poole, Dorset, United Kingdom, BH15 2JB
      • Poole Hospital NHS Foundation Trust, Poole General Hospital
  • England
    • Plymouth, England, United Kingdom, PL68DH
      • Derriford Hospital
    • West Bromwich, England, United Kingdom, B71 4HJ
      • Sandwell & West Birmingham Hospitals NHS Trust
  • Northern Ireland
    • Antrim, Northern Ireland, United Kingdom, BT41 2RL
      • Antrim Area Hospital
  • Scotland
    • Glasgow, Scotland, United Kingdom, G11 6NT
      • NHS Greater Glasgow and Clyde Western Infirmary
• United States
  • Michigan
    • Novi, Michigan, United States, 48377
      • Detroit Clinical Research Center, PC
  • New York
    • New York, New York, United States, 10021
      • New York Presbyterian Hospital
    • New York, New York, United States, 10065
      • Memorial Sloan-Kettering Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient has one of the following peripheral T-cell lymphoma (PTCL) subtypes confirmed by an independent central pathology reviewer, using the Revised European American Lymphoma World Health Organization disease classification:

  • T/natural killer (NK)-cell leukemia/lymphoma
  • Adult T-cell lymphoma (TCL)/leukemia (human T-cell leukemia virus 1+)
  • Angioimmunoblastic TCL
  • Anaplastic large cell lymphoma (ALCL), primary systemic type, excluding anaplastic lymphoma kinase positive (ALK+) with International Prognostic Index (IPI) score less than 2 at initial diagnosis and complete response (CR) after CHOP-based therapy
  • PTCL-unspecified
  • Enteropathy-type intestinal lymphoma
  • Hepatosplenic TCL
  • Subcutaneous panniculitis TCL
  • Transformed mycosis fungoides (tMF)
  • Extranodal T/NK-cell lymphoma nasal or nasal type
  • Primary cutaneous gamma-delta TCL
  • Primary cutaneous CD8+ aggressive epidermic cytotoxic TCL

• Documented completion of at least 6 cycles of CHOP-based therapy:

  • CHOP 21
  • CHOP 14
  • CHOP + etoposide
  • Other CHOP variants: substitution allowed for 1 component with a drug of the same mechanism of action. Additional components, except alemtuzumab, are allowed. Rituximab may be added if not given within 3 cycles of randomization.
• Patient has achieved CR or partial response (PR) per per investigator's assessment following completion of CHOP-based therapy and has had radiological assessment within 21 days prior to randomization.
• Eastern Cooperative Oncology Group performance status less than or equal to 2.
• Adequate blood, liver, and kidney function as defined by laboratory tests.
• Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate.
• Men who are sexually active, including those with a pregnant partner, must agree to practice a medically acceptable barrier method contraceptive regimen (eg, condoms) while receiving pralatrexate and for 90 days after the last administration of pralatrexate.
• Has given written informed consent.

Exclusion Criteria:

• Patient has:

  • Precursor T/NK neoplasms
  • ALCL (ALK+) with IPI score less than 2 at initial diagnosis and CR after CHOP-based therapy
  • T cell prolymphocytic leukemia
  • T cell large granular lymphocytic leukemia
  • Mycosis fungoides, except tMF
  • Sézary syndrome
  • Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis

• If there is a history of prior malignancies other than those below, must be disease free for at least 5 years. Patients with malignancies listed below less than 5 years before study entry may be enrolled if they have received treatment resulting in complete resolution of the cancer and have no clinical, radiologic, or laboratory evidence of active/recurrent disease.

  • non-melanoma skin cancer
  • carcinoma in situ of the cervix
  • localized prostate cancer
  • localized thyroid cancer

• Receipt of prior chemotherapy (CT) or radiation therapy (RT) for PTCL, other than a single allowed CHOP regimen, except:

  • Patients with nasal NK lymphoma who received local RT less than 4 weeks prior to randomization.
  • Patients with tMF who received 1 systemic single-agent CT (except methotrexate) prior to transformation.
• Prior exposure to pralatrexate.
• Receipt of systemic corticosteroids within 3 weeks of study treatment, unless patient has been taking a continuous dose of 10 mg/day or less of oral prednisone or equivalent for at least 4 weeks or as part of a CHOP prednisone taper.
• Planned use of any treatment for PTCL during the course of the study.

• Patient has:

  • Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.
  • Hepatitis B (HBV)-positive serology and is receiving interferon therapy or has liver function test results outside the parameters of study inclusion criteria. Other antiviral therapies are permitted if at a stable dose for at least 4 weeks.
  • Hepatitis C (HCV) virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy.
  • Symptomatic central nervous system metastases or lesions requiring treatment.
  • Uncontrolled hypertension or congestive heart failure Class III/IV per the New York Heart Association's Heart Failure Guidelines
  • Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness impairing the ability of the patient to receive protocol treatment.
• Major surgery within 2 weeks prior to study entry, except for line placement or biopsy procedure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pralatrexate; Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.	Drug: Pralatrexate Injection; Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride). Initial dose: 30 mg/m2 Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.; Other Names: FOLOTYN; PDX; Pralatrexate; (RS)-10-propargyl-10-deazaaminopterin
No Intervention: Observation; Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	PFS was defined as the time in days from randomization to the date of objective documentation of progressive disease (PD) or death, regardless of cause (date of PD or death - date of randomization + 1). PFS was to be assessed according to the International Workshop Criteria (IWC) without including positron emission tomography (PET). PD was defined as any new lesion or increase by greater than or equal to (>=) 50 percent (%) of previously involved sites from nadir. Participants who were alive without a disease response assessment of PD was to be censored at their last disease assessment date or the date of randomization, whichever was later. Date of progression was not to be imputed for participants with missing tumor assessments before an assessment of PD. Participants who withdraw from treatment prior to PD were to be followed for disease status whenever possible. Participants who have no response assessments after baseline were to be censored at randomization.	From randomization to the date of progression of disease or death due to any cause (up to 76 months)
Overall Survival (OS)	Overall survival was defined as the time in days from randomization to the date of death, regardless of cause (date of death - date of randomization + 1).	From randomization until death (up to 76 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate	Objective response rate was defined as percentage of participants with an objective response of complete response (CR) or partial response (PR), relative to disease status at the time of study entry. The percentage was to be calculated by dividing number of participants within each category of response by the number of participants with measurable disease at baseline. Objective response was assessed according to the IWC without including PET. CR was defined as complete disappearance all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR was defined as regression of measurable disease and no new sites.	Up to 2 years
Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Serious Adverse Events (SAEs), and SAEs Leading to Discontinuation of Study Treatment, and Worst Grade Laboratory Abnormalities	An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. AE included both serious and non- SAEs. An AE of "Hematology and Chemistry" was collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening and Grade 4 refers to life-threatening consequences.	From first dose of study drug to 35 (±5) days after last dose of study drug for the Pralatrexate Arm, and until 35 (± 5) days after the study treatment discontinuation for the Observation Arm (Up to 2 years)

Collaborators and Investigators

• Sponsor: Spectrum Pharmaceuticals, Inc

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2011
• Primary Completion (Actual): December 1, 2017
• Study Completion (Actual): December 1, 2017

Study Registration Dates

• First Submitted: August 18, 2011
• First Submitted That Met QC Criteria: August 19, 2011
• First Posted (Estimate): August 22, 2011

Study Record Updates

• Last Update Posted (Actual): November 19, 2021
• Last Update Submitted That Met QC Criteria: November 18, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: Lymphoma; Non-Hodgkin's Lymphoma; Lymphoproliferative Disorders; T-cell Lymphoma
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Folic Acid Antagonists; 10-deazaaminopterin; Aminopterin
• Other Study ID Numbers: PDX-017; 2010-022230-81 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No